17 results on '"Chau, Gordon"'
Search Results
2. Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study.
- Author
-
Seneviratne, Herana Kamal, Seneviratne, Herana Kamal, Hamlin, Allyson N, Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Kuo, Irene, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Adeyeye, Adeola, Rinehart, Alex R, McCauley, Marybeth, Eron, Joseph S, Cohen, Myron S, Landovitz, Raphael J, Hendrix, Craig W, Bumpus, Namandjé N, Seneviratne, Herana Kamal, Seneviratne, Herana Kamal, Hamlin, Allyson N, Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Kuo, Irene, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Adeyeye, Adeola, Rinehart, Alex R, McCauley, Marybeth, Eron, Joseph S, Cohen, Myron S, Landovitz, Raphael J, Hendrix, Craig W, and Bumpus, Namandjé N
- Abstract
Cabotegravir (CAB) is an integrase strand-transfer inhibitor of HIV that has proven effective for HIV treatment and prevention in a long-acting injectable formulation, typically preceded by an oral formulation lead-in phase. Previous in vitro studies have demonstrated that CAB is primarily metabolized via glucuronidation by uridine diphosphate glucuronosyltransferase (UGT) 1A1 and 1A9. In this study, we performed next-generation sequencing of genomic DNA isolated from the HPTN 077 participants to explore the variants within UGT1A1 and UGT1A9. Additionally, to enable correlation of UGT1A1 and UGT1A9 genotypes with plasma CAB-glucuronide levels, we quantified glucuronidated CAB following both oral administration of CAB and intramuscular injection of long-acting CAB. From these studies, 48 previously unreported variants of UGT1A1 and UGT1A9 were detected. Notably, 5/68 individuals carried a UGT1A1 454C>A variant that resulted in amino acid substitution P152T, and the use of in silico tools predicted a deleterious effect of the P152T substitution. Thus, the impact of this mutant on a range of UGT1A1 substrates was tested using a COS-7 cell-based assay. The glucuronide conjugates of CAB, dolutegravir, and raltegravir, were not formed in the COS-7 cells expressing the UGT1A1 P152T mutant. Further, formation of glucuronides of raloxifene and 7-ethyl-10-hydroxycamptothecin were reduced in the cells expressing the UGT1A1 P152T mutant. Using the same approach, we tested the activities of two UGT1A9 mutants, UGT1A9 H217Y and UGT1A9 R464G, and found that these mutations were tolerated and decreased function, respectively. These data provide insight into previously unreported genetic variants of UGT1A1 and UGT1A9.
- Published
- 2021
3. Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study.
- Author
-
Seneviratne, Herana Kamal, Seneviratne, Herana Kamal, Hamlin, Allyson N, Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Kuo, Irene, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Adeyeye, Adeola, Rinehart, Alex R, McCauley, Marybeth, Eron, Joseph S, Cohen, Myron S, Landovitz, Raphael J, Hendrix, Craig W, Bumpus, Namandjé N, Seneviratne, Herana Kamal, Seneviratne, Herana Kamal, Hamlin, Allyson N, Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Kuo, Irene, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Adeyeye, Adeola, Rinehart, Alex R, McCauley, Marybeth, Eron, Joseph S, Cohen, Myron S, Landovitz, Raphael J, Hendrix, Craig W, and Bumpus, Namandjé N
- Abstract
Cabotegravir (CAB) is an integrase strand-transfer inhibitor of HIV that has proven effective for HIV treatment and prevention in a long-acting injectable formulation, typically preceded by an oral formulation lead-in phase. Previous in vitro studies have demonstrated that CAB is primarily metabolized via glucuronidation by uridine diphosphate glucuronosyltransferase (UGT) 1A1 and 1A9. In this study, we performed next-generation sequencing of genomic DNA isolated from the HPTN 077 participants to explore the variants within UGT1A1 and UGT1A9. Additionally, to enable correlation of UGT1A1 and UGT1A9 genotypes with plasma CAB-glucuronide levels, we quantified glucuronidated CAB following both oral administration of CAB and intramuscular injection of long-acting CAB. From these studies, 48 previously unreported variants of UGT1A1 and UGT1A9 were detected. Notably, 5/68 individuals carried a UGT1A1 454C>A variant that resulted in amino acid substitution P152T, and the use of in silico tools predicted a deleterious effect of the P152T substitution. Thus, the impact of this mutant on a range of UGT1A1 substrates was tested using a COS-7 cell-based assay. The glucuronide conjugates of CAB, dolutegravir, and raltegravir, were not formed in the COS-7 cells expressing the UGT1A1 P152T mutant. Further, formation of glucuronides of raloxifene and 7-ethyl-10-hydroxycamptothecin were reduced in the cells expressing the UGT1A1 P152T mutant. Using the same approach, we tested the activities of two UGT1A9 mutants, UGT1A9 H217Y and UGT1A9 R464G, and found that these mutations were tolerated and decreased function, respectively. These data provide insight into previously unreported genetic variants of UGT1A1 and UGT1A9.
- Published
- 2021
4. Correction to 'Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study'.
- Author
-
Seneviratne, Herana Kamal, Seneviratne, Herana Kamal, Hamlin, Allyson N, Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Kuo, Irene, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Adeyeye, Adeola, Rinehart, Alex R, McCauley, Marybeth, Eron, Joseph J, Cohen, Myron S, Landovitz, Raphael J, Hendrix, Craig W, Bumpus, Namandjé N, Seneviratne, Herana Kamal, Seneviratne, Herana Kamal, Hamlin, Allyson N, Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Kuo, Irene, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Adeyeye, Adeola, Rinehart, Alex R, McCauley, Marybeth, Eron, Joseph J, Cohen, Myron S, Landovitz, Raphael J, Hendrix, Craig W, and Bumpus, Namandjé N
- Abstract
[This corrects the article DOI: 10.1021/acsptsci.0c00181.].
- Published
- 2021
5. Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.
- Author
-
Landovitz, Raphael J, Landovitz, Raphael J, Zangeneh, Sahar Z, Chau, Gordon, Grinsztejn, Beatriz, Eron, Joseph J, Dawood, Halima, Magnus, Manya, Liu, Albert Y, Panchia, Ravindre, Hosseinipour, Mina C, Kofron, Ryan, Margolis, David A, Rinehart, Alex, Adeyeye, Adeola, Burns, David, McCauley, Marybeth, Cohen, Myron S, Currier, Judith S, Landovitz, Raphael J, Landovitz, Raphael J, Zangeneh, Sahar Z, Chau, Gordon, Grinsztejn, Beatriz, Eron, Joseph J, Dawood, Halima, Magnus, Manya, Liu, Albert Y, Panchia, Ravindre, Hosseinipour, Mina C, Kofron, Ryan, Margolis, David A, Rinehart, Alex, Adeyeye, Adeola, Burns, David, McCauley, Marybeth, Cohen, Myron S, and Currier, Judith S
- Abstract
Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.
- Published
- 2020
6. Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077.
- Author
-
Blair, Cheríe S, Blair, Cheríe S, Li, Sue, Chau, Gordon, Cottle, Leslie, Richardson, Paul, Marzinke, Mark A, Eshleman, Susan H, Adeyeye, Adeola, Rinehart, Alex R, Margolis, David, McCauley, Marybeth, Hendrix, Craig W, Landovitz, Raphael J, HPTN 077 Study Team, Blair, Cheríe S, Blair, Cheríe S, Li, Sue, Chau, Gordon, Cottle, Leslie, Richardson, Paul, Marzinke, Mark A, Eshleman, Susan H, Adeyeye, Adeola, Rinehart, Alex R, Margolis, David, McCauley, Marybeth, Hendrix, Craig W, Landovitz, Raphael J, and HPTN 077 Study Team
- Abstract
ObjectivesTo evaluate whether hormonal contraceptive use among cisgender women is associated with differences in pharmacokinetic (PK) parameters of a long-acting injectable formulation of the integrase strand transfer inhibitor, cabotegravir (CAB-LA).SettingThis is a secondary analysis of 85 cisgender women enrolled in HPTN 077, a phase 2a multicenter study that enrolled HIV-uninfected, low-risk individuals in Malawi, Brazil, South Africa, and the United States.MethodsParticipants received 4-week daily oral cabotegravir lead-in, followed by CAB-LA 800 mg injection every 12 weeks (cohort 1) or 600 mg every 8 weeks (after 4-week initial interval between injections, cohort 2), over 41 weeks. Participants were followed 52-76 weeks subsequent to final injection. Generalized estimating equations and linear regression were used to evaluate differences in CAB-LA PK parameters (peak concentration, trough concentration, area under the curve, apparent terminal half-life, and time to lower limit of quantification) and self-reported hormonal contraceptive stratified by type (oral, injectable, implants, and other), controlling for body mass index and cohort.ResultsCompared to women reporting no hormonal contraception (n = 6), oral contraceptive use (n = 18) was associated with lower CAB-LA peak concentration but was not associated with differences in other PK parameters. No other hormonal contraceptive type (injectable, implants, and other) was associated with significant differences in CAB-LA PK parameters.ConclusionAlthough oral contraceptive use was associated with differences in CAB-LA peak concentration, no differences were observed in other PK parameters, suggesting that this association is not likely to be clinically significant. However, these data highlight the need for further research exploring potential drug-drug interactions between CAB-LA and hormonal contraceptives.
- Published
- 2020
7. Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077.
- Author
-
Tolley, Elizabeth E, Tolley, Elizabeth E, Zangeneh, Sahar Z, Chau, Gordon, Eron, Joe, Grinsztejn, Beatriz, Humphries, Hilton, Liu, Albert, Siegel, Marc, Bertha, Maseko, Panchia, Ravindre, Li, Sue, Cottle, Leslie, Rinehart, Alex, Margolis, David, Jennings, Andrea, McCauley, Marybeth, Landovitz, Raphael J, Tolley, Elizabeth E, Tolley, Elizabeth E, Zangeneh, Sahar Z, Chau, Gordon, Eron, Joe, Grinsztejn, Beatriz, Humphries, Hilton, Liu, Albert, Siegel, Marc, Bertha, Maseko, Panchia, Ravindre, Li, Sue, Cottle, Leslie, Rinehart, Alex, Margolis, David, Jennings, Andrea, McCauley, Marybeth, and Landovitz, Raphael J
- Abstract
Long-acting injectable PrEP could offer an alternative to daily oral PrEP, improve adherence and protection, if found acceptable, safe and effective. HPTN 077 evaluated injectable cabotegravir safety, tolerability and pharmacokinetics among HIV-uninfected males and females in sequentially-enrolled cohorts of two dosing strategies. We compared acceptability of product attributes, prevention preferences and future interest in injectable PrEP (FIIP) by region, sex-at-birth, arm and cohort and used multivariable analysis to identify FIIP determinants. Baseline injectable PrEP preferences were higher in non-U.S. sites and increased in both regions over time. In multivariable models, FIIP was most strongly associated with acceptability of product attributes, was higher in non-U.S. sites and more altruistic participants. Treatment arm and report of pain were not associated with FIIP. Injectable acceptability was highest in non-U.S. sites. Preferences for injectable versus other PrEP methods were higher among U.S. males than females, but higher among males and females in non-U.S. settings.
- Published
- 2020
8. Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.
- Author
-
Landovitz, Raphael J, Landovitz, Raphael J, Zangeneh, Sahar Z, Chau, Gordon, Grinsztejn, Beatriz, Eron, Joseph J, Dawood, Halima, Magnus, Manya, Liu, Albert Y, Panchia, Ravindre, Hosseinipour, Mina C, Kofron, Ryan, Margolis, David A, Rinehart, Alex, Adeyeye, Adeola, Burns, David, McCauley, Marybeth, Cohen, Myron S, Currier, Judith S, Landovitz, Raphael J, Landovitz, Raphael J, Zangeneh, Sahar Z, Chau, Gordon, Grinsztejn, Beatriz, Eron, Joseph J, Dawood, Halima, Magnus, Manya, Liu, Albert Y, Panchia, Ravindre, Hosseinipour, Mina C, Kofron, Ryan, Margolis, David A, Rinehart, Alex, Adeyeye, Adeola, Burns, David, McCauley, Marybeth, Cohen, Myron S, and Currier, Judith S
- Abstract
Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.
- Published
- 2020
9. Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077.
- Author
-
Tolley, Elizabeth E, Tolley, Elizabeth E, Zangeneh, Sahar Z, Chau, Gordon, Eron, Joe, Grinsztejn, Beatriz, Humphries, Hilton, Liu, Albert, Siegel, Marc, Bertha, Maseko, Panchia, Ravindre, Li, Sue, Cottle, Leslie, Rinehart, Alex, Margolis, David, Jennings, Andrea, McCauley, Marybeth, Landovitz, Raphael J, Tolley, Elizabeth E, Tolley, Elizabeth E, Zangeneh, Sahar Z, Chau, Gordon, Eron, Joe, Grinsztejn, Beatriz, Humphries, Hilton, Liu, Albert, Siegel, Marc, Bertha, Maseko, Panchia, Ravindre, Li, Sue, Cottle, Leslie, Rinehart, Alex, Margolis, David, Jennings, Andrea, McCauley, Marybeth, and Landovitz, Raphael J
- Abstract
Long-acting injectable PrEP could offer an alternative to daily oral PrEP, improve adherence and protection, if found acceptable, safe and effective. HPTN 077 evaluated injectable cabotegravir safety, tolerability and pharmacokinetics among HIV-uninfected males and females in sequentially-enrolled cohorts of two dosing strategies. We compared acceptability of product attributes, prevention preferences and future interest in injectable PrEP (FIIP) by region, sex-at-birth, arm and cohort and used multivariable analysis to identify FIIP determinants. Baseline injectable PrEP preferences were higher in non-U.S. sites and increased in both regions over time. In multivariable models, FIIP was most strongly associated with acceptability of product attributes, was higher in non-U.S. sites and more altruistic participants. Treatment arm and report of pain were not associated with FIIP. Injectable acceptability was highest in non-U.S. sites. Preferences for injectable versus other PrEP methods were higher among U.S. males than females, but higher among males and females in non-U.S. settings.
- Published
- 2020
10. Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077.
- Author
-
Blair, Cheríe S, Blair, Cheríe S, Li, Sue, Chau, Gordon, Cottle, Leslie, Richardson, Paul, Marzinke, Mark A, Eshleman, Susan H, Adeyeye, Adeola, Rinehart, Alex R, Margolis, David, McCauley, Marybeth, Hendrix, Craig W, Landovitz, Raphael J, HPTN 077 Study Team, Blair, Cheríe S, Blair, Cheríe S, Li, Sue, Chau, Gordon, Cottle, Leslie, Richardson, Paul, Marzinke, Mark A, Eshleman, Susan H, Adeyeye, Adeola, Rinehart, Alex R, Margolis, David, McCauley, Marybeth, Hendrix, Craig W, Landovitz, Raphael J, and HPTN 077 Study Team
- Abstract
ObjectivesTo evaluate whether hormonal contraceptive use among cisgender women is associated with differences in pharmacokinetic (PK) parameters of a long-acting injectable formulation of the integrase strand transfer inhibitor, cabotegravir (CAB-LA).SettingThis is a secondary analysis of 85 cisgender women enrolled in HPTN 077, a phase 2a multicenter study that enrolled HIV-uninfected, low-risk individuals in Malawi, Brazil, South Africa, and the United States.MethodsParticipants received 4-week daily oral cabotegravir lead-in, followed by CAB-LA 800 mg injection every 12 weeks (cohort 1) or 600 mg every 8 weeks (after 4-week initial interval between injections, cohort 2), over 41 weeks. Participants were followed 52-76 weeks subsequent to final injection. Generalized estimating equations and linear regression were used to evaluate differences in CAB-LA PK parameters (peak concentration, trough concentration, area under the curve, apparent terminal half-life, and time to lower limit of quantification) and self-reported hormonal contraceptive stratified by type (oral, injectable, implants, and other), controlling for body mass index and cohort.ResultsCompared to women reporting no hormonal contraception (n = 6), oral contraceptive use (n = 18) was associated with lower CAB-LA peak concentration but was not associated with differences in other PK parameters. No other hormonal contraceptive type (injectable, implants, and other) was associated with significant differences in CAB-LA PK parameters.ConclusionAlthough oral contraceptive use was associated with differences in CAB-LA peak concentration, no differences were observed in other PK parameters, suggesting that this association is not likely to be clinically significant. However, these data highlight the need for further research exploring potential drug-drug interactions between CAB-LA and hormonal contraceptives.
- Published
- 2020
11. Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.
- Author
-
Zangeneh, Sahar, Zangeneh, Sahar, Chau, Gordon, Grinsztejn, Beatriz, Eron, Joseph, Dawood, Halima, Magnus, Manya, Liu, Albert, Panchia, Ravindre, Hosseinipour, Mina, Kofron, Ryan, Margolis, David, Rinehart, Alex, Adeyeye, Adeola, Burns, David, McCauley, Marybeth, Cohen, Myron, Currier, Judith, Landovitz, Raphael, Zangeneh, Sahar, Zangeneh, Sahar, Chau, Gordon, Grinsztejn, Beatriz, Eron, Joseph, Dawood, Halima, Magnus, Manya, Liu, Albert, Panchia, Ravindre, Hosseinipour, Mina, Kofron, Ryan, Margolis, David, Rinehart, Alex, Adeyeye, Adeola, Burns, David, McCauley, Marybeth, Cohen, Myron, Currier, Judith, and Landovitz, Raphael
- Abstract
Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.
- Published
- 2020
12. The Longitudinal Effects of Non-injection Substance Use on Sustained HIV Viral Load Undetectability Among MSM and Heterosexual Men in Brazil and Thailand: The Role of ART Adherence and Depressive Symptoms (HPTN 063).
- Author
-
Tsuyuki, Kiyomi, Tsuyuki, Kiyomi, Shoptaw, Steven J, Ransome, Yusuf, Chau, Gordon, Rodriguez-Diaz, Carlos E, Friedman, Ruth K, Srithanaviboonchai, Kriengkrai, Li, Sue, Mimiaga, Matthew J, Mayer, Kenneth H, Safren, Steven A, Tsuyuki, Kiyomi, Tsuyuki, Kiyomi, Shoptaw, Steven J, Ransome, Yusuf, Chau, Gordon, Rodriguez-Diaz, Carlos E, Friedman, Ruth K, Srithanaviboonchai, Kriengkrai, Li, Sue, Mimiaga, Matthew J, Mayer, Kenneth H, and Safren, Steven A
- Abstract
The effect of non-injection substance use on HIV viral load (VL) is understudied in international settings. Data are from HPTN063, a longitudinal observational study of HIV-infected individuals in Brazil, Thailand, and Zambia, with focus on men with VL data (Brazil = 146; Thailand = 159). Generalized linear mixed models (GLMM) assessed whether non-injection substance use (stimulants, cannabis, alcohol, polysubstance) was associated with VL undetectability. ART adherence and depressive symptoms were examined as mediators of the association. In Thailand, substance use was not significantly associated with VL undetectability or ART adherence, but alcohol misuse among MSM was associated with increased odds of depression (AOR = 2.75; 95% CI 1.20, 6.32, p = 0.02). In Brazil, alcohol misuse by MSM was associated with decreased odds of undetectable VL (AOR = 0.34; 95% CI 0.13, 0.92, p = 0.03). Polysubstance use by heterosexual men in Brazil was associated with decreased odds of ART adherence (AOR = 0.25; 95% CI 0.08, 0.78, p = 0.02). VL suppression appears attainable among non-injection substance users. Substance use interventions among HIV-positive men should address depression, adherence, and VL undetectability.
- Published
- 2019
13. The Longitudinal Effects of Non-injection Substance Use on Sustained HIV Viral Load Undetectability Among MSM and Heterosexual Men in Brazil and Thailand: The Role of ART Adherence and Depressive Symptoms (HPTN 063).
- Author
-
Tsuyuki, Kiyomi, Tsuyuki, Kiyomi, Shoptaw, Steven J, Ransome, Yusuf, Chau, Gordon, Rodriguez-Diaz, Carlos E, Friedman, Ruth K, Srithanaviboonchai, Kriengkrai, Li, Sue, Mimiaga, Matthew J, Mayer, Kenneth H, Safren, Steven A, Tsuyuki, Kiyomi, Tsuyuki, Kiyomi, Shoptaw, Steven J, Ransome, Yusuf, Chau, Gordon, Rodriguez-Diaz, Carlos E, Friedman, Ruth K, Srithanaviboonchai, Kriengkrai, Li, Sue, Mimiaga, Matthew J, Mayer, Kenneth H, and Safren, Steven A
- Abstract
The effect of non-injection substance use on HIV viral load (VL) is understudied in international settings. Data are from HPTN063, a longitudinal observational study of HIV-infected individuals in Brazil, Thailand, and Zambia, with focus on men with VL data (Brazil = 146; Thailand = 159). Generalized linear mixed models (GLMM) assessed whether non-injection substance use (stimulants, cannabis, alcohol, polysubstance) was associated with VL undetectability. ART adherence and depressive symptoms were examined as mediators of the association. In Thailand, substance use was not significantly associated with VL undetectability or ART adherence, but alcohol misuse among MSM was associated with increased odds of depression (AOR = 2.75; 95% CI 1.20, 6.32, p = 0.02). In Brazil, alcohol misuse by MSM was associated with decreased odds of undetectable VL (AOR = 0.34; 95% CI 0.13, 0.92, p = 0.03). Polysubstance use by heterosexual men in Brazil was associated with decreased odds of ART adherence (AOR = 0.25; 95% CI 0.08, 0.78, p = 0.02). VL suppression appears attainable among non-injection substance users. Substance use interventions among HIV-positive men should address depression, adherence, and VL undetectability.
- Published
- 2019
14. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
- Author
-
Landovitz, Raphael J, Landovitz, Raphael J, Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Magnus, Manya, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A, Hendrix, Craig W, Eshleman, Susan H, Zhang, Yinfeng, Tolley, Elizabeth, Sugarman, Jeremy, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R, Margolis, David, Spreen, William R, Cohen, Myron S, McCauley, Marybeth, Eron, Joseph J, Landovitz, Raphael J, Landovitz, Raphael J, Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Magnus, Manya, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A, Hendrix, Craig W, Eshleman, Susan H, Zhang, Yinfeng, Tolley, Elizabeth, Sugarman, Jeremy, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R, Margolis, David, Spreen, William R, Cohen, Myron S, McCauley, Marybeth, and Eron, Joseph J
- Abstract
BackgroundCabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular (IM) administration, which delivers prolonged plasma exposure to the drug after IM injection. HIV Prevention Trials Network study 077 (HPTN 077) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States.Methods and findingsHPTN 077 was a double-blind, placebo-controlled phase 2a trial. Healthy individuals age 18-65 years at low HIV risk were randomized (3:1) to receive CAB or placebo (PBO). In the initial oral phase, participants received 1 daily oral tablet (CAB or PBO) for 4 weeks. Those without safety concerns in the oral phase continued and received injections in the injection phase (Cohort 1: 3 injections of CAB LA 800 mg or 0.9% saline as PBO IM every 12 weeks for 3 injection cycles; Cohort 2: CAB LA 600 mg or PBO IM for 5 injection cycles; the first 2 injections in Cohort 2 were separated by 4 weeks, the rest by 8 weeks). The primary analysis included weeks 5 to 41 of study participation, encompassing the injection phase. The cohorts were enrolled sequentially. Primary outcomes were safety and tolerability. Secondary outcomes included pharmacokinetics and events occurring during the oral and injection phases. Between February 9, 2015, and May 27, 2016, the study screened 443 individuals and enrolled 110 participants in Cohort 1 and 89 eligible participants in Cohort 2. Participant population characteristics were as follows: 66% female at birth; median age 31 years; 27% non-Hispanic white, 41% non-Hispanic black, 24% Hispanic/Latino, 3% Asian, and 6% mixed/other; and 6 transgender men and 1 transgender woman. Twenty-two (11%) participants discontinued the ora
- Published
- 2018
15. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
- Author
-
Landovitz, Raphael J, Newell, Marie-Louise1, Landovitz, Raphael J, Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Magnus, Manya, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A, Hendrix, Craig W, Eshleman, Susan H, Zhang, Yinfeng, Tolley, Elizabeth, Sugarman, Jeremy, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R, Margolis, David, Spreen, William R, Cohen, Myron S, McCauley, Marybeth, Eron, Joseph J, Landovitz, Raphael J, Newell, Marie-Louise1, Landovitz, Raphael J, Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Magnus, Manya, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A, Hendrix, Craig W, Eshleman, Susan H, Zhang, Yinfeng, Tolley, Elizabeth, Sugarman, Jeremy, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R, Margolis, David, Spreen, William R, Cohen, Myron S, McCauley, Marybeth, and Eron, Joseph J
- Abstract
BackgroundCabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular (IM) administration, which delivers prolonged plasma exposure to the drug after IM injection. HIV Prevention Trials Network study 077 (HPTN 077) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States.Methods and findingsHPTN 077 was a double-blind, placebo-controlled phase 2a trial. Healthy individuals age 18-65 years at low HIV risk were randomized (3:1) to receive CAB or placebo (PBO). In the initial oral phase, participants received 1 daily oral tablet (CAB or PBO) for 4 weeks. Those without safety concerns in the oral phase continued and received injections in the injection phase (Cohort 1: 3 injections of CAB LA 800 mg or 0.9% saline as PBO IM every 12 weeks for 3 injection cycles; Cohort 2: CAB LA 600 mg or PBO IM for 5 injection cycles; the first 2 injections in Cohort 2 were separated by 4 weeks, the rest by 8 weeks). The primary analysis included weeks 5 to 41 of study participation, encompassing the injection phase. The cohorts were enrolled sequentially. Primary outcomes were safety and tolerability. Secondary outcomes included pharmacokinetics and events occurring during the oral and injection phases. Between February 9, 2015, and May 27, 2016, the study screened 443 individuals and enrolled 110 participants in Cohort 1 and 89 eligible participants in Cohort 2. Participant population characteristics were as follows: 66% female at birth; median age 31 years; 27% non-Hispanic white, 41% non-Hispanic black, 24% Hispanic/Latino, 3% Asian, and 6% mixed/other; and 6 transgender men and 1 transgender woman. Twenty-two (11%) participants discontinued the ora
- Published
- 2018
16. Analysis of HIV Diversity in HIV-Infected Black Men Who Have Sex with Men (HPTN 061).
- Author
-
Chen, Iris, Chen, Iris, Chau, Gordon, Wang, Jing, Clarke, William, Marzinke, Mark A, Cummings, Vanessa, Breaud, Autumn, Laeyendecker, Oliver, Fields, Sheldon D, Griffith, Sam, Scott, Hyman M, Shoptaw, Steven, Del Rio, Carlos, Magnus, Manya, Mannheimer, Sharon, Tieu, Hong-Van, Wheeler, Darrell P, Mayer, Kenneth H, Koblin, Beryl A, Eshleman, Susan H, Chen, Iris, Chen, Iris, Chau, Gordon, Wang, Jing, Clarke, William, Marzinke, Mark A, Cummings, Vanessa, Breaud, Autumn, Laeyendecker, Oliver, Fields, Sheldon D, Griffith, Sam, Scott, Hyman M, Shoptaw, Steven, Del Rio, Carlos, Magnus, Manya, Mannheimer, Sharon, Tieu, Hong-Van, Wheeler, Darrell P, Mayer, Kenneth H, Koblin, Beryl A, and Eshleman, Susan H
- Abstract
BackgroundHIV populations often diversify in response to selective pressures, such as the immune response and antiretroviral drug use. We analyzed HIV diversity in Black men who have sex with men who were enrolled in the HIV Prevention Trials Network 061 study.MethodsA high resolution melting (HRM) diversity assay was used to measure diversity in six regions of the HIV genome: two in gag, one in pol, and three in env. HIV diversity was analyzed for 146 men who were HIV infected at study enrollment, including three with acute infection and 13 with recent infection (identified using a multi-assay algorithm), and for 21 men who seroconverted during the study. HIV diversification was analyzed in a paired analysis for 62 HIV-infected men using plasma samples from the enrollment and 12-month (end of study) visits.ResultsMen with acute or recent infection at enrollment and seroconverters had lower median HRM scores (lower HIV diversity) than men with non-recent infection in all six regions analyzed. In univariate analyses, younger age, higher CD4 cell count, and HIV drug resistance were associated with lower median HRM scores in multiple regions; ARV drug detection was marginally associated with lower diversity in the pol region. In multivariate analysis, acute or recent infection (all six regions) and HIV drug resistance (both gag regions) were associated with lower median HRM scores. Diversification in the pol region over 12 months was greater for men with acute or recent infection, higher CD4 cell count, and lower HIV viral load at study enrollment.ConclusionsHIV diversity was significantly associated with duration of HIV infection, and lower gag diversity was observed in men who had HIV drug resistance. HIV pol diversification was more pronounced in men with acute or recent infection, higher CD4 cell count, and lower HIV viral load.
- Published
- 2016
17. Analysis of HIV Diversity in HIV-Infected Black Men Who Have Sex with Men (HPTN 061).
- Author
-
Chen, Iris, Mammano, Fabrizio1, Chen, Iris, Chau, Gordon, Wang, Jing, Clarke, William, Marzinke, Mark A, Cummings, Vanessa, Breaud, Autumn, Laeyendecker, Oliver, Fields, Sheldon D, Griffith, Sam, Scott, Hyman M, Shoptaw, Steven, Del Rio, Carlos, Magnus, Manya, Mannheimer, Sharon, Tieu, Hong-Van, Wheeler, Darrell P, Mayer, Kenneth H, Koblin, Beryl A, Eshleman, Susan H, Chen, Iris, Mammano, Fabrizio1, Chen, Iris, Chau, Gordon, Wang, Jing, Clarke, William, Marzinke, Mark A, Cummings, Vanessa, Breaud, Autumn, Laeyendecker, Oliver, Fields, Sheldon D, Griffith, Sam, Scott, Hyman M, Shoptaw, Steven, Del Rio, Carlos, Magnus, Manya, Mannheimer, Sharon, Tieu, Hong-Van, Wheeler, Darrell P, Mayer, Kenneth H, Koblin, Beryl A, and Eshleman, Susan H
- Abstract
BackgroundHIV populations often diversify in response to selective pressures, such as the immune response and antiretroviral drug use. We analyzed HIV diversity in Black men who have sex with men who were enrolled in the HIV Prevention Trials Network 061 study.MethodsA high resolution melting (HRM) diversity assay was used to measure diversity in six regions of the HIV genome: two in gag, one in pol, and three in env. HIV diversity was analyzed for 146 men who were HIV infected at study enrollment, including three with acute infection and 13 with recent infection (identified using a multi-assay algorithm), and for 21 men who seroconverted during the study. HIV diversification was analyzed in a paired analysis for 62 HIV-infected men using plasma samples from the enrollment and 12-month (end of study) visits.ResultsMen with acute or recent infection at enrollment and seroconverters had lower median HRM scores (lower HIV diversity) than men with non-recent infection in all six regions analyzed. In univariate analyses, younger age, higher CD4 cell count, and HIV drug resistance were associated with lower median HRM scores in multiple regions; ARV drug detection was marginally associated with lower diversity in the pol region. In multivariate analysis, acute or recent infection (all six regions) and HIV drug resistance (both gag regions) were associated with lower median HRM scores. Diversification in the pol region over 12 months was greater for men with acute or recent infection, higher CD4 cell count, and lower HIV viral load at study enrollment.ConclusionsHIV diversity was significantly associated with duration of HIV infection, and lower gag diversity was observed in men who had HIV drug resistance. HIV pol diversification was more pronounced in men with acute or recent infection, higher CD4 cell count, and lower HIV viral load.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.